2019 New Treatment Guidelines for Peyronie's Disease
Urological Associations recommends combining the Penile Traction Devices of Andromedical with Collagenase injections to treat Peyronie.
NEW YORK, November 29, 2018 (Newswire.com) - Andromedical Laboratory has patented and researched Penile Traction Devices for 20 years to develop ANDROPEYRONIE ®, a medical device to treat Peyronie's disease. Based on a clinical study published in The Journal of Sexual Medicine (Nov-2013, Dr. Martínez-Salamanca et al.), ANDROPEYRONIE ® reduces the penile curvature in more than 50 percent, with a pain reduction, an increasing in penile length of 1.5 cm and an improvement in the sexual function. ANDROPEYRONIE ® is the only device registered by the U.S. Food and Drug Administration for PD. More information in: https://www.andropeyronie.com
The new guidelines, presented by the Canadian Urological Association (CUA) in 2018, recommend the use of remodeling technique based on Penile Traction Device of Andromedical (ANDROPEYRONIE®) in combination with collagenase injections to treat patients with Peyronie's disease (PD).
Canadian Urological Association recommends penile remodeling with mechanical therapy or penile traction: The use of a traction device to reduce plaque/wound contracture, enhance plaque elasticity, and reduce plaque size is appealing, given its low cost and general freedom from adverse effects. Traction impact on PD cells in a mechanical strained environment results in alteration of connective tissue, demonstrating measurable changes in collagen and tissue metalloproteinase expression, which are two key factors in determining plaque integrity. It appears to have some activity in correcting penile pain, curvature, and maintenance of penile length, with recent reports highlighting a potential synergy with intralesional or oral agents. The current treatment paradigm for PD relies on tissue remodeling for optimal outcomes following both minimally invasive treatment approaches and post-surgical results. More information.
Also, American Urological Association (AUA) in 2015 recommended to medical professionals administer intralesional collagenase clostridium histolyticum in combination with modeling (penile traction therapy) by the physician and by the patient for the decrease of penile curvature in people with stable PD, with a penile curvature > 30 degrees and also < 90 degrees, and intact erectile function. More information.
Dr. Eduardo Gomez, inventor of the Penile Traction Device (PTT), explains, "I recommend a minimum of 8 hours/daily of use for the PTT devices. With less hours, no result is obtained. The future of PD treatment is the combination of penile traction with collagenase injections to obtain the best outcomes, as recommended by urological associations." More information about Penile Traction Devices.
Andromedical is a urology Laboratory with ISO 13485 Medical Device Certified which focuses on men's health devices. Our mission is an improvement in the male sexual function and a correction of penile morphology. We hold health certifications as USA FDA Registration, Canada CMDCAS, CE Declaration of Conformity and Australia ARTG. More company information.
Dr. Eduardo Gomez de Diego
Tags: bent penis, collagenase, curved penis, penile curvature, penile traction device, penile traction therapy, penis extender, Peyronie, Peyronie's disease, Peyronie's disease therapy, Peyronie's disease treatment